Rachel Sachs breaks down a final rule from CMS establishing the framework for the Medicare Drug Price Negotiation Program and evaluates how the Trump administration's broader drug pricing policy ...

The decisive midterm elections will have significant implications for a wide range of health policy priorities—in Congress, ...

Advocates for Head Start are faced with the question of whether the program can remain as effective without the same ...

Despite lower negotiated prices, uncertainty around GLP-1 uptake, budget exposure, and long-term cost offsets may limit state participation in BALANCE.

MD, MA, is a former Washington, DC, public school teacher, where he taught middle school science and completed a master’s degree in the arts of teaching at American University. He completed his ...

The answer lies in a powerful narrative circulating for years before the FDA convened its panel, one that recast the original ...

MPH, is a social science research analyst at the Centers for Medicare and Medicaid Services (CMS) Innovation Center where she supports a variety of payment and care delivery models in designing and ...

We have now seen AI going from renewing prescriptions to writing them in less than a year. The next step will likely be ...

Alon Bergman, PhD, is an assistant professor of medical ethics and health policy at the Perelman School of Medicine at the University of Pennsylvania, where he studies provider behavior, medical ...

Pharmaceutical Research and Manufacturers of America, a drug manufacturer trade group, challenged the final rule on GLOBE ...

CMS should develop a GLP-1 Total Cost of Care Scorecard that integrates spending across Medicare Parts A, B, and D; stratifies outcomes by beneficiary risk; and explicitly measures the economics of ...

Thani Jambulingam, PhD, is the Dick Warren ’50 Sesquicentennial Chair of Business and professor in the Department of Pharmaceutical and Healthcare Marketing at the Erivan K. Haub School of Business, ...